MindMed | Investor Presentation Deck | 28 slides

MindMed · 2025-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

28
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
front_matter
04
The slide uses a timeline framework to map clinical trial progress against calendar periods.plan_implementation
05
The chart uses a Gantt-style visualization to represent clinical trial progress.plan_implementation
06
The slide uses a combination of clinical data points and qualitative stakeholder feedback to establish the problem.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
07
Uses a 'Before-After' framing structure.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
Data compares all psychiatric providers vs interventional psychiatric providers across two survey questions.show_traction
Open slide detailBeat · ProblemLoop · Cost Of Inaction
09
transition
10
Uses a process flow diagram to illustrate the biological mechanism from receptor activation to clinical outcome.present_solution
11
The slide uses a visual metaphor of a cluttered, anxious mind alongside a list of clinical and economic impacts.frame_problem
Open slide detailBeat · Agitate
12
Includes a large callout for the primary prevalence statistic and a list of clinical/economic impacts.frame_problem
Open slide detailBeat · Agitate
13
The slide outlines a multi-arm clinical development strategy with standardized trial designs (Part A/B) across different indications.plan_implementation
14
Includes clinical trial data references and definitions for CGI-S and HAM-A.compare_peers
Open slide detailBeat · Evidence & Proof
15
The slide presents two line charts comparing MM120 (100 µg) against placebo across two primary clinical endpoints.show_traction
Open slide detailBeat · Evidence & Proof
16
The slide uses a line chart to show longitudinal symptom reduction and a bar chart to show categorical outcomes (responders/remitters).show_traction
Open slide detailBeat · Evidence & Proof
17
The slide uses a structured layout with three distinct categories of safety findings (tolerability, SAEs, suicidality).analyze_data
18
The slide outlines a two-part study design (Part A: Randomized/Double-Blind, Part B: Open-Label Extension) with specific patient counts and dosing regimens.plan_implementation
19
The slide outlines two study arms (MM120 ODT 100 µg and Placebo) with a primary endpoint at week 6, followed by a 40-week extension.plan_implementation
20
The slide uses a linked-circle diagram to represent a sequence or interconnected set of regulatory requirements.establish_context
21
transition
22
The central diagram is a circular hub-and-spoke model representing the MM120 Value Proposition.plan_implementation
Open slide detailLoop · Quick Win Big Bet
23
The 'Quadruple Aim' is a well-known healthcare framework. The visual is a quadrant diagram.present_solution
Open slide detailLoop · Quick Win Big Bet
24
The slide highlights the existing infrastructure for Spravato as a proxy for the potential launch environment for MindMed.establish_context
Open slide detailLoop · Quick Win Big Bet
25
The slide uses a structured table to map clinical workflow to billing codes.plan_implementation
27
The slide outlines two parallel studies (Voyage and Panorama) with specific participant counts and dosing regimens.plan_implementation
28
The slide uses a structured list format to map specific clinical trial risks to mitigation strategies.plan_implementation